Hematology focuses on blood disorders, including anemia
and leukemia, examining their impact on red and white blood cells
and plasma proteins. This analysis highlights current therapies,
technologies, and diagnostic approaches for prevention and
treatment.
BOSTON, July 25,
2024 /PRNewswire/ -- According to the
latest BCC Research study, the demand for "Drugs and
Diagnostics for Hematological Disorders: Global Markets" is
expected to grow from $131.2 billion
in 2024 and is projected to reach $189.3
billion by the end of 2029, at a compound annual growth rate
(CAGR) of 7.6% during the forecast period of 2024 to 2029.
![BCC Research LLC Logo BCC Research LLC Logo](https://mma.prnewswire.com/media/2183242/BCC_Research_Logo.jpg)
The global market for drugs used to treat hematological
disorders, along with the devices and reagents used for their
diagnosis, is categorized based on product type into reagents &
instruments, and software. By end user, the market segments include
hospitals, diagnostic labs, and others. Hematological disorder
treatments are further divided into oncology drugs and non-oncology
drugs. Geographically, the market spans North America, Europe, Asia-Pacific, and the Rest of the World (RoW).
The report provides market estimates using 2023 as the base year,
with forecasts extending from 2024 through 2029. It also includes
details on approved drugs, pipeline analysis, innovative research,
market opportunities, and profiles of leading companies. A key
driver of market growth is the increasing incidence of leukemia,
which has spurred the development of more effective treatment
options.
This report is particularly relevant at this moment due to the
complexity of blood as an organ, which is associated with a wide
range of hematologic disorders and diseases. Each of these
conditions is unique, yet blood serves as a common link among them.
The increasing prevalence of various blood-related diseases—such as
cancers, anemias, hemoglobinopathies, bone marrow failure
syndromes, bleeding disorders, platelet disorders, blood clots,
plasma cell disorders, and numerous rare diseases—is driving
significant growth in the market.
Please click here for more details on "The global
market for drugs and diagnostics for hematological disorders
Report."
The following factors drive the global market for drugs and
diagnostics for hematological disorders:
High Incidence of Blood Disorders: Blood disorders like
anemia, sickle cell anemia, and leukemia affect a large segment of
the global population, driving the need for effective treatments
and diagnostic tools. The rising awareness of these conditions
emphasizes the necessity for ongoing research and innovation.
Government and Private Funding: Both government agencies
and private investors are increasingly funding initiatives to
combat hematological disorders. This financial support is essential
for developing new therapies and improving access to existing
treatments, ultimately enhancing patient care.
Automation in Hematology: Automation in hematology has
streamlined laboratory processes, increasing efficiency and
accuracy in diagnostics. Technologies like automated blood cell
counters and coagulation analyzers enhance the speed and
reliability of test results, minimizing human error.
Advancements in Diagnosis: Innovations such as flow
cytometry, molecular testing, and genetic profiling have improved
the precision of diagnosing blood disorders. Early detection
through these advanced methods facilitates timely interventions and
personalized treatment strategies, leading to better patient
outcomes.
Request a Sample Copy of the global market for drugs
and diagnostics for hematological disorders Report.
Report Synopsis
Report
Metrics
|
Details
|
Base year
considered
|
2023
|
Forecast Period
considered
|
2024-2029
|
Base year market
size
|
$122.2
billion
|
Market Size
Forecast
|
$189.3
billion
|
Growth rate
|
CAGR of 7.6% for the
forecast period of 2024-2029
|
Segment
Covered
|
Segment, Product, End
User, Drug Type, and Region
|
Regions
covered
|
North America, Europe,
Asia-Pacific, and Rest of the World (RoW)
|
Key Market
Drivers
|
- High incidence of
blood disorders
- Increasing
government and private funding for treatment
- Rising use of
automation
- Advances in the
diagnosis of hematology disorders
|
Key Interesting Facts About the global market
for drugs and diagnostics for hematological disorders:
Cell-Based Gene Therapies for Sickle Cell
Disease (SCD):
- The U.S. FDA approved the first cell-based gene therapies for
SCD in December 2023.
- These treatments are specifically for patients aged 12 years
and older.
- The groundbreaking therapies are named Casgevy and
Lyfgenia.
Ciltacabtagene Autoleucel (Cilta-cel)
Approval:
- In April 2024, Johnson &
Johnson announced the approval of ciltacabtagene autoleucel
(Carvykti).
- Cilta-cel is a second-line therapy for patients with refractory
SCD.
- It is used when lenalidomide (Revlimid) and a proteasome
inhibitor are ineffective in prior treatment.
The global market for drugs and diagnostics
for hematological disorders report includes in-depth data and
analysis addressing the following important queries:
- What is the projected market size and growth rate of the
market?
• The global drugs and diagnostics for
hematological disorders market was valued at $122.2 billion in 2023 and is expected to reach
$189.3 billion by the end of 2029.
The market is expected to witness a CAGR of 7.6% from 2024 to
2029.
- What are the key factors driving the growth of the
market?
• Key factors that are driving the growth are
the high incidence and prevalence of blood disorders, increasing
government and private funding for treatment, rising adoption of
automation, and advancement in the diagnosis of hematology
disorders.
- What segments are covered in the market?
• The
global drugs and diagnostics for hematological disorders market is
segmented based on market, drug type, product type, end-user, and
region.
- By market, which segment will dominate the market by the end
of 2029?
• The hematology drugs segment will dominate
the market in 2029.
- Which region has the highest market share in the
market?
• North
America holds the highest share of the market.
Some of the Key Market Players Are:
- ABBOTT
- BIO-RAD LABORATORIES INC.
- DANAHER CORP.
- NOVARTIS AG
- SYSMEX CORP.
- AMGEN INC.
- BRISTOL MYERS SQUIBB CO.
- F. HOFFMANN-LA ROCHE LTD.
- SANOFI
- TAKEDA PHARMACEUTICAL CO. LTD.
Browse More Related Report:
Next-Generation Cancer Diagnostics: Technologies and Global
Markets: This report analyzes next-generation diagnostic
technologies, including NGS, PCR, and liquid biopsy platforms,
comparing them to tissue-based testing. It highlights major
research initiatives driving cancer diagnostics and provides an
in-depth look at key companies in the market. The analysis covers
cancer sites (e.g., breast, lung, colorectal), test purposes
(screening, diagnosis, monitoring), test platforms, and
geographical regions (North
America, Europe,
Asia-Pacific, Rest of the World).
The base year is 2021, with historical data from 2019-2020 and
forecasts through 2027.
Hematology Analyzer Market: This report offers a
detailed analysis of the hematology analyzer market, focusing on
current and future potential, key drivers, and challenges. It
includes market projections through 2028, competitive landscape
insights, and regulatory factors, along with product and end-user
segmentation. Key players are profiled with information on their
business segments, financials, and recent developments. The report
also assesses the impact of COVID-19 and provides geographical
segmentation across North America,
Europe, Asia-Pacific, and the Rest of the World, with
historical data from 2020-2021 and forecasts through 2028.
Directly Purchase a copy of the
report with BCC Research.
For further information or to make a purchase, please get in
touch with info@bccresearch.com.
About BCC Research
BCC Research provides objective, unbiased measurement and
assessment of market opportunities with detailed market research
reports. Our experienced industry analysts' goal is to help you
make informed business decisions, free of noise and hype.
Contact Us
Corporate HQ: 50 Milk St. Ste 16,
Boston, MA 02109, USA
info@bccresearch.com,
+1 781-489-7301
For media inquiries, email press@bccresearch.com or
visit our media page for access to our market research library.
Data and analysis extracted from this press release must be
accompanied by a statement identifying BCC Research
LLC as the source and publisher.
Logo:
https://mma.prnewswire.com/media/2183242/BCC_Research_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/revolutionary-advances-in-hematological-therapies-and-diagnostics-global-market-insights-by-bcc-research-302206280.html
SOURCE BCC Research LLC